Carmustine – Uses, Dosage, Side Effects, Interaction Carmustine (BCNU) is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of several forms of cancer including leukemias, lymphomas, and breast, testicular, ovarian, gastric, and pancreatic cancer. Carmustine therapy is associated with minor transient serum enzyme elevations and has been linked to cases of acute liver injury including cholestatic hepatitis and acute venous-occlusive disease. Carmustine is an antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04) Carmustine is a member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound. Mechanism of Action Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production, and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death. Temozolomide (TMZ) and carmustine (BCNU), cancer drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine. It has been shown that 06-methylguanine triggers DNA mismatch repair and in turn induces apoptosis and senescence, respectively, over a 4 and 6 days period. Temozolomide and carmustine have an earlier effect on the nuclear organization and chromatin structure. In particular, temozolomide and carmustine induce the clustering of pericentromeric heterochromatin regions and increase the number of heterochromatic proteins MeCP2 and HP1alpha bound to chromatin. These drugs also decrease global levels of histone H3 acetylation and increase levels of histone H3 trimethylated on lysine 9 (H3-triMeK9). These events precede the senescence status. … Temozolomide and carmustine efficacy in glioma treatment may implicate a first event characterized by changes in heterochromatin organization and its silencing which is then followed by apoptosis and senescence. Indications For the treatment of brain tumors, multiple myeloma, Hodgkin’s disease, and Non-Hodgkin’s lymphomas. Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumors (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma, and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous hematopoietic progenitor cell transplantation (HPCT) in malignant hematological diseases. Astrocytomas Brain Stem Gliomas Ependymomas Glioblastoma Multiforme (GBM) Medulloblastomas Mycosis Fungoides (MF) Newly Diagnosed High Grade Glioma (HGG) Recurrent Glioblastoma Multiforme (GBM) Refractory Hodgkin Lymphoma Refractory Multiple Myeloma Tumors Metastatic to Brain Refractory Non-Hodgkin’s lymphoma Use in Cancer Carmustine is approved to be used alone or with other drugs to treat: Brain tumors (certain types). Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back). Multiple myeloma. It is used with prednisone. Non-Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back). Carmustine is also being studied in the treatment of other types of cancer. Contraindication a bad infection acute leukemia anemia decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils bleeding a condition where there is formation of fibrous tissue in the lung called pulmonary fibrosis x-ray results showing lung tissue changes liver problems decreased kidney function abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 100 mg; 7.7 mg; 50 mg; 300 mg Brain/Intracranial Tumor IV: As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days) In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly. Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide: Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose. Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma in combination with prednisone Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs Non-Hodgkin’s Lymphoma IV: As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days) In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly. Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide: Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose. Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose. IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma in combination with prednisone Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs Hodgkin’s Disease IV: As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days) In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly. Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide: Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose. Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose. IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma in combination with prednisone Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs Multiple Myeloma IV: As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days) In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly. Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide: Nadir after the prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose. Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose. Nadir after the prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose. IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma in combination with prednisone Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs Glioblastoma Multiforme WAFER: Eight 7.7 mg wafers (61.6 mg total dose) were implanted intracranially WAFER: Newly-diagnosed high-grade glioma as an adjunct to surgery and radiation Recurrent glioblastoma as an adjunct to surgery Malignant Glioma WAFER: Eight 7.7 mg wafers (61.6 mg total dose) were implanted intracranially Side Effects The Most Common nausea vomiting headache loss of balance or coordination pale skin fainting dizziness fast or irregular heartbeat chest pain darkened skin swelling, pain, redness, or burning at the injection site Signs of an allergic reaction such as hives, rash, skin changes, difficulty breathing or talking, or swelling of the mouth, face, lips, tongue, or throat. Nausea (interferes with the ability to eat and is unrelieved with prescribed medication). upset stomach extreme tiredness or weakness lack of energy loss of appetite pain in the upper right part of the stomach yellowing of the skin or eyes decreased urination swelling of the hands, feet, ankles, or lower legs Carmustine injection may cause other side effects. More Common easy bruising, unusual bleeding; a seizure; unexplained weight loss; little or no urination; or pain, burning, swelling, or skin changes where the injection was given; slow healing of your incision after carmustine implant placement; lung problems–a dry cough or hack, shortness of breath (especially with exercise), rapid but shallow breathing, tiredness, body aches, clubbing (widening and rounding) of your fingertips or toes; increased pressure inside your skull–sudden vision problems, severe headache, vomiting, dizziness; or signs of meningitis–fever, neck stiffness, increased sensitivity to light, nausea, vomiting, confusion, and drowsiness. Rare difficulty breathing, swelling of your face, lips, tongue, or throat, skin redness, eye redness, severe warmth or tingling under your skin, easy bruising, unusual bleeding, seizure, unexplained weight loss, little or no urination, pain, burning, swelling, or skin changes where the injection was given, slow healing of your incision after implant placement, dry cough or hack, shortness of breath, rapid bur shallow breathing, tiredness, body aches, clubbing (widening and rounding) of your fingertips or toes, sudden vision problems, severe headache, vomiting, dizziness, neck stiffness, increased sensitivity to light, confusion, and drowsiness Interaction DRUG INTERACTION Abacavir Carmustine may decrease the excretion rate of Abacavir which could result in a higher serum level. Abametapir The serum concentration of Carmustine can be increased when it is combined with Abametapir. Abatacept The metabolism of Carmustine can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Carmustine. Abiraterone The serum concentration of Carmustine can be increased when it is combined with Abiraterone. Aceclofenac Aceclofenac may decrease the excretion rate of Carmustine which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Carmustine which could result in a higher serum level. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Carmustine. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Carmustine. Acetazolamide Acetazolamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Carmustine. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Carmustine. Aclidinium Carmustine may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Carmustine may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir The metabolism of Acyclovir can be decreased when combined with Carmustine. Adalimumab The metabolism of Carmustine can be increased when combined with Adalimumab. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Carmustine which could result in a higher serum level. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Carmustine. Agomelatine The metabolism of Agomelatine can be decreased when combined with Carmustine. Albendazole The metabolism of Carmustine can be increased when combined with Albendazole. Albutrepenonacog alfa Carmustine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Carmustine which could result in a higher serum level. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carmustine. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Carmustine. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Carmustine. Almasilate Carmustine may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Carmustine may decrease the excretion rate of Almotriptan which could result in a higher serum level. Alogliptin Carmustine may decrease the excretion rate of Alogliptin which could result in a higher serum level. Alosetron The metabolism of Carmustine can be decreased when combined with Alosetron. Alprazolam Carmustine may decrease the excretion rate of Alprazolam which could result in a higher serum level. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Carmustine. Altretamine The risk or severity of adverse effects can be increased when Carmustine is combined with Altretamine. Amantadine Carmustine may decrease the excretion rate of Amantadine which could result in a higher serum level. Amikacin Carmustine may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride Amiloride may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Carmustine. Aminophylline The metabolism of Aminophylline can be decreased when combined with Carmustine. Amiodarone The metabolism of Carmustine can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Carmustine. Ammonium chloride Carmustine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amoxicillin Carmustine may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Carmustine which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Carmustine which could result in a higher serum level. Ampicillin Carmustine may decrease the excretion rate of Ampicillin which could result in a higher serum level. Amrinone Carmustine may decrease the excretion rate of Amrinone which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Carmustine is combined with Amsacrine. Anagrelide The metabolism of Carmustine can be decreased when combined with Anagrelide. Anakinra The metabolism of Carmustine can be increased when combined with Anakinra. Anastrozole The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Anastrozole. Ancestim Carmustine may decrease the excretion rate of Ancestim which could result in a higher serum level. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Carmustine. Anifrolumab The risk or severity of adverse effects can be increased when Carmustine is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Carmustine. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carmustine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Carmustine. Antihemophilic Carmustine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antilymphocyte The risk or severity of adverse effects can be increased when Carmustine is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be decreased when combined with Carmustine. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carmustine. Antithrombin III human Carmustine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine. Antrafenine Antrafenine may decrease the excretion rate of Carmustine which could result in a higher serum level. Apalutamide Carmustine may decrease the excretion rate of Apalutamide which could result in a higher serum level. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Carmustine. Apremilast The metabolism of Carmustine can be increased when combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Carmustine. Arformoterol Carmustine may decrease the excretion rate of Arformoterol which could result in a higher serum level. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Carmustine. Armodafinil The metabolism of Carmustine can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Carmustine is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Articaine. Asenapine The metabolism of Asenapine can be decreased when combined with Carmustine. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Carmustine. Atazanavir The metabolism of Carmustine can be decreased when combined with Atazanavir. Atomoxetine Carmustine may decrease the excretion rate of Atomoxetine which could result in a higher serum level. Auranofin Carmustine may decrease the excretion rate of Auranofin which could result in a higher serum level. Aurothioglucose Carmustine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Carmustine. Azacitidine The risk or severity of adverse effects can be increased when Carmustine is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Carmustine is combined with Azathioprine. Azelaic acid Carmustine may decrease the excretion rate of Azelaic acid which could result in a higher serum level. Azelastine The metabolism of Azelastine can be decreased when combined with Carmustine. Aztreonam Carmustine may decrease the excretion rate of Aztreonam which could result in a higher serum level. Bacillus calmette- The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Carmustine. Bacillus calmette- The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Carmustine. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Carmustine. Bacitracin Bacitracin may decrease the excretion rate of Carmustine which could result in a higher serum level. Baclofen Baclofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Balsalazide Balsalazide may decrease the excretion rate of Carmustine which could result in a higher serum level. Baricitinib The risk or severity of adverse effects can be increased when Carmustine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Carmustine. Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Carmustine is combined with Beclomethasone dipropionate. Belatacept The risk or severity of adverse effects can be increased when Carmustine is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Carmustine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Carmustine is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Carmustine is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Carmustine. Bendamustine The risk or severity of adverse effects can be increased when Carmustine is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Carmustine which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Benserazide Carmustine may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Carmustine which could result in a higher serum level. Benznidazole Carmustine may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Benzocaine. Benzthiazide Benzthiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Carmustine which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Benzyl alcohol. Bepotastine Carmustine may decrease the excretion rate of Bepotastine which could result in a higher serum level. Betamethasone The risk or severity of adverse effects can be increased when Carmustine is combined with Betamethasone. Betaxolol The metabolism of Carmustine can be decreased when combined with Betaxolol. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Carmustine. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Carmustine. Bexarotene The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene. Bicisate Carmustine may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The metabolism of Carmustine can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Carmustine. Bismuth subgallate Carmustine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol Carmustine may decrease the excretion rate of Bisoprolol which could result in a higher serum level. Bisoxatin Carmustine may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Carmustine. Bleomycin The risk or severity of adverse effects can be increased when Carmustine is combined with Bleomycin. Blinatumomab The risk or severity of adverse effects can be increased when Carmustine is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Carmustine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Carmustine. Bosutinib The risk or severity of adverse effects can be increased when Carmustine is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Carmustine is combined with Brentuximab vedotin. Brivaracetam Carmustine may decrease the excretion rate of Brivaracetam which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Carmustine is combined with Brodalumab. Bromazepam The metabolism of Bromazepam can be decreased when combined with Carmustine. Bromotheophylline Bromotheophylline may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Budesonide The risk or severity of adverse effects can be increased when Carmustine is combined with Budesonide. Bumadizone Bumadizone may decrease the excretion rate of Carmustine which could result in a higher serum level. Bumetanide Bumetanide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Bupivacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Bupivacaine. Bupropion Carmustine may decrease the excretion rate of Bupropion which could result in a higher serum level. Buspirone Carmustine may decrease the excretion rate of Buspirone which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Carmustine is combined with Busulfan. Butabarbital Butabarbital may decrease the excretion rate of Carmustine which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Carmustine is combined with Cabazitaxel. Caffeine The metabolism of Carmustine can be decreased when combined with Caffeine. Canagliflozin Canagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The metabolism of Carmustine can be increased when combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Carmustine. Cannabidiol The metabolism of Carmustine can be decreased when combined with Cannabidiol. Canrenoic acid Canrenoic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Carmustine is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Carmustine. Capmatinib The metabolism of Carmustine can be decreased when combined with Capmatinib. Capreomycin Carmustine may decrease the excretion rate of Capreomycin which could result in a higher serum level. Capsaicin The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Carmustine is combined with Carbamazepine. Carbidopa Carbidopa may decrease the excretion rate of Carmustine which could result in a higher serum level. Carboplatin The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Carmustine is combined with Carfilzomib. Carprofen Carprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Carvedilol The metabolism of Carvedilol can be decreased when combined with Carmustine. Cefaclor Cefaclor may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefdinir Carmustine may decrease the excretion rate of Cefdinir which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Carmustine which could result in a higher serum level. Ceftolozane Carmustine may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Carmustine which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Carmustine which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Carmustine which could result in a higher serum level. Cephalexin Cephalexin may decrease the excretion rate of Carmustine which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Carmustine which could result in a higher serum level. Certolizumab pegol The metabolism of Carmustine can be increased when combined with Certolizumab pegol. Cetirizine Carmustine may decrease the excretion rate of Cetirizine which could result in a higher serum level. Cevimeline Cevimeline may decrease the excretion rate of Carmustine which could result in a higher serum level. Chloral hydrate Carmustine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Chloramphenicol The risk or severity of adverse effects can be increased when Carmustine is combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Chloroprocaine. Chloroquine Carmustine may decrease the excretion rate of Chloroquine which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Carmustine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Carmustine. Chlorpropamide Carmustine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Carmustine. Choline C 11 Carmustine may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Carmustine which could result in a higher serum level. Choline salicylate Carmustine may decrease the excretion rate of Choline salicylate which could result in a higher serum level. Chondroitin sulfate Carmustine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Carmustine may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Carmustine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Carmustine may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gluconate Carmustine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Carmustine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Carmustine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Carmustine is combined with Ciclesonide. Cidofovir Cidofovir may decrease the excretion rate of Carmustine which could result in a higher serum level. Cilostazol The metabolism of Cilostazol can be decreased when combined with Carmustine. Cimetidine Cimetidine may increase the myelosuppressive activities of Carmustine. Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Carmustine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Carmustine. Cinoxacin The metabolism of Carmustine can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Carmustine can be decreased when combined with Ciprofloxacin. Cisplatin The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin. Citalopram The metabolism of Carmustine can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Carmustine. Clevidipine Carmustine may decrease the excretion rate of Clevidipine which could result in a higher serum level. Clobazam Carmustine may decrease the excretion rate of Clobazam which could result in a higher serum level. Clobetasol propionate The risk or severity of adverse effects can be increased when Carmustine is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Carmustine is combined with Clofarabine. Clomipramine The metabolism of Clomipramine can be decreased when combined with Carmustine. Clonazepam Carmustine may decrease the excretion rate of Clonazepam which could result in a higher serum level. Clonidine The metabolism of Clonidine can be decreased when combined with Carmustine. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Carmustine. Clorazepic acid Carmustine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carmustine. Clove oil Carmustine may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine The risk or severity of neutropenia can be increased when Carmustine is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Cocaine. Colchicine Carmustine may decrease the excretion rate of Colchicine which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Carmustine which could result in a higher serum level. Colistin Carmustine may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Carmustine. Corifollitropin alfa Carmustine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Corticotropin The risk or severity of adverse effects can be increased when Carmustine is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Carmustine is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carmustine. Curcumin The metabolism of Carmustine can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carmustine. Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Carmustine. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The risk or severity of adverse effects can be increased when Carmustine is combined with Cyclophosphamide. Cyclosporine Carmustine may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Cyproterone acetate The metabolism of Carmustine can be increased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Carmustine. Dabigatran etexilate Carmustine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dacarbazine The risk or severity of adverse effects can be increased when Carmustine is combined with Dacarbazine. Dactinomycin The risk or severity of adverse effects can be increased when Carmustine is combined with Dactinomycin. Dalfampridine Carmustine may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Carmustine. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Carmustine. Dapagliflozin Dapagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmustine. Dasatinib The risk or severity of adverse effects can be increased when Carmustine is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Carmustine is combined with Decitabine. Deferasirox The serum concentration of Carmustine can be increased when it is combined with Deferasirox. Deferiprone Carmustine may decrease the excretion rate of Deferiprone which could result in a higher serum level. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Carmustine. Deflazacort The risk or severity of adverse effects can be increased when Carmustine is combined with Deflazacort. Delafloxacin Carmustine may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Carmustine. Desipramine Carmustine may decrease the excretion rate of Desipramine which could result in a higher serum level. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Carmustine. Deslanoside Deslanoside may decrease the cardiotoxic activities of Carmustine. Desmopressin Desmopressin may decrease the excretion rate of Carmustine which could result in a higher serum level. Desoximetasone The risk or severity of adverse effects can be increased when Carmustine is combined with Desoximetasone. Desvenlafaxine Carmustine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Carmustine is combined with Deucravacitinib. Deutetrabenazine Carmustine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexamethasone The risk or severity of adverse effects can be increased when Carmustine is combined with Dexamethasone. Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Carmustine. Dexibuprofen Dexibuprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Dexmedetomidine The metabolism of Carmustine can be decreased when combined with Dexmedetomidine. Dexpanthenol Carmustine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane. Dextran Carmustine may decrease the excretion rate of Dextran which could result in a higher serum level. Diacerein The metabolism of Carmustine can be decreased when combined with Diacerein. Diatrizoate Carmustine may decrease the excretion rate of Diatrizoate which could result in a higher serum level. Diazepam Carmustine may decrease the excretion rate of Diazepam which could result in a higher serum level. Dichlorobenzyl alcohol Carmustine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac The metabolism of Diclofenac can be decreased when combined with Carmustine. Diclofenamide Diclofenamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Carmustine. Dicyclomine Carmustine may decrease the excretion rate of Dicyclomine which could result in a higher serum level. Didanosine Carmustine may decrease the excretion rate of Didanosine which could result in a higher serum level. Dienogest Carmustine may decrease the excretion rate of Dienogest which could result in a higher serum level. Diflunisal Diflunisal may decrease the excretion rate of Carmustine which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Carmustine is combined with Difluocortolone. Digitoxin Digitoxin may decrease the cardiotoxic activities of Carmustine. Digoxin Carmustine may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydralazine The metabolism of Carmustine can be decreased when combined with Dihydralazine. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level. Dimercaprol Carmustine may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Carmustine is combined with Dimethyl fumarate. Dimethyl sulfoxide Carmustine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. Dinutuximab The risk or severity of adverse effects can be increased when Carmustine is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Carmustine. Diroximel fumarate The risk or severity of adverse effects can be increased when Carmustine is combined with Diroximel fumarate. Disopyramide The metabolism of Disopyramide can be decreased when combined with Carmustine. DL-Methylephedrine Carmustine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Carmustine may decrease the excretion rate of Dobutamine which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Carmustine is combined with Docetaxel. Domperidone The metabolism of Domperidone can be decreased when combined with Carmustine. Dopamine Carmustine may decrease the excretion rate of Dopamine which could result in a higher serum level. Doripenem Carmustine may decrease the excretion rate of Doripenem which could result in a higher serum level. Dosulepin The metabolism of Carmustine can be decreased when combined with Dosulepin. Doxacurium Carmustine may decrease the excretion rate of Doxacurium which could result in a higher serum level. Doxepin The metabolism of Doxepin can be decreased when combined with Carmustine. Doxorubicin The risk or severity of adverse effects can be increased when Carmustine is combined with Doxorubicin. Doxycycline Doxycycline may decrease the excretion rate of Carmustine which could result in a higher serum level. Dronabinol The metabolism of Carmustine can be decreased when combined with Dronabinol. Drospirenone Drospirenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carmustine. Droxidopa Carmustine may decrease the excretion rate of Droxidopa which could result in a higher serum level. Duloxetine Carmustine may decrease the excretion rate of Duloxetine which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Dyclonine. Dyphylline Carmustine may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Carmustine. Eculizumab The risk or severity of adverse effects can be increased when Carmustine is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Carmustine. Edoxaban Carmustine may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Carmustine may decrease the excretion rate of Edrophonium which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine. Efavirenz The metabolism of Carmustine can be decreased when combined with Efavirenz. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Carmustine. Emapalumab The metabolism of Carmustine can be increased when combined with Emapalumab. Enalaprilat Carmustine may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Enasidenib The metabolism of Carmustine can be decreased when combined with Enasidenib. Enoxacin The metabolism of Carmustine can be decreased when combined with Enoxacin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Carmustine. Entecavir The metabolism of Entecavir can be decreased when combined with Carmustine. Enzalutamide Carmustine may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epirubicin The risk or severity of adverse effects can be increased when Carmustine is combined with Epirubicin. Eplerenone Eplerenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Carmustine. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Carmustine. Eribulin The risk or severity of adverse effects can be increased when Carmustine is combined with Eribulin. Erlotinib The metabolism of Erlotinib can be decreased when combined with Carmustine. Ertapenem Carmustine may decrease the excretion rate of Ertapenem which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carmustine. Estazolam Carmustine may decrease the excretion rate of Estazolam which could result in a higher serum level. Estradiol The metabolism of Estradiol can be decreased when combined with Carmustine. Estradiol acetate The metabolism of Carmustine can be decreased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Carmustine. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Carmustine. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Carmustine. Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Carmustine. Estramustine The risk or severity of adverse effects can be increased when Carmustine is combined with Estramustine. Estrone sulfate The metabolism of Carmustine can be decreased when combined with Estrone sulfate. Eszopiclone Carmustine may decrease the excretion rate of Eszopiclone which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Carmustine may decrease the excretion rate of Etafedrine which could result in a higher serum level. Etanercept The metabolism of Carmustine can be increased when combined with Etanercept. Ethambutol Carmustine may decrease the excretion rate of Ethambutol which could result in a higher serum level. Ethanol The metabolism of Ethanol can be decreased when combined with Carmustine. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Carmustine. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Etidocaine. Etodolac Etodolac may decrease the excretion rate of Carmustine which could result in a higher serum level. Etomidate Carmustine may decrease the excretion rate of Etomidate which could result in a higher serum level. Etonogestrel Carmustine may decrease the excretion rate of Etonogestrel which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Carmustine is combined with Etoposide. Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Carmustine. Eucalyptus oil Carmustine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Carmustine is combined with Everolimus. Ezogabine Carmustine may decrease the excretion rate of Ezogabine which could result in a higher serum level. Famotidine The metabolism of Carmustine can be decreased when combined with Famotidine. Fenbufen Fenbufen may decrease the excretion rate of Carmustine which could result in a higher serum level. Fenfluramine The metabolism of Fenfluramine can be decreased when combined with Carmustine. Fenofibrate Carmustine may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fenofibric acid Carmustine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Carmustine may decrease the excretion rate of Fenoldopam which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Fentanyl Carmustine may decrease the excretion rate of Fentanyl which could result in a higher serum level. Fesoterodine Carmustine may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Fexinidazole The metabolism of Carmustine can be decreased when combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Carmustine is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Carmustine may increase the immunosuppressive activities of Fingolimod. Flavoxate Carmustine may decrease the excretion rate of Flavoxate which could result in a higher serum level. Flecainide The metabolism of Flecainide can be decreased when combined with Carmustine. Floctafenine Floctafenine may decrease the excretion rate of Carmustine which could result in a higher serum level. Florbetaben (18F) Carmustine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir (18F) Carmustine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Carmustine is combined with Floxuridine. Fluconazole Fluconazole may decrease the excretion rate of Carmustine which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Carmustine is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Carmustine is combined with Fludarabine. Fludeoxyglucose (18F) Carmustine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Fludrocortisone The risk or severity of adverse effects can be increased when Carmustine is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Carmustine. Flumazenil Carmustine may decrease the excretion rate of Flumazenil which could result in a higher serum level. Flunarizine The metabolism of Flunarizine can be decreased when combined with Carmustine. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Carmustine. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorometholone. Fluorouracil The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil. Fluoxetine The metabolism of Carmustine can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carmustine. Fluprednisolone The risk or severity of adverse effects can be increased when Carmustine is combined with Fluprednisolone. Flurazepam Carmustine may decrease the excretion rate of Flurazepam which could result in a higher serum level. Flurbiprofen Flurbiprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. Flutamide The metabolism of Flutamide can be decreased when combined with Carmustine. Fluticasone The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone propionate. Fluvoxamine The metabolism of Carmustine can be decreased when combined with Fluvoxamine. Folic acid Folic acid may decrease the excretion rate of Carmustine which could result in a higher serum level. Fomepizole Carmustine may decrease the excretion rate of Fomepizole which could result in a higher serum level. Fondaparinux Carmustine may decrease the excretion rate of Fondaparinux which could result in a higher serum level. Formestane Carmustine may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet Foscarnet may decrease the excretion rate of Carmustine which could result in a higher serum level. Fosfomycin Carmustine may decrease the excretion rate of Fosfomycin which could result in a higher serum level. Fosinopril Carmustine may decrease the excretion rate of Fosinopril which could result in a higher serum level. Fosphenytoin The serum concentration of Fosphenytoin can be decreased when it is combined with Carmustine. Framycetin Framycetin may decrease the excretion rate of Carmustine which could result in a higher serum level. Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Carmustine. Furosemide Furosemide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Gabapentin enacarbil Carmustine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Carmustine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Carmustine which could result in a higher serum level. Gadofosveset trisodium Carmustine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Carmustine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Gadoteric acid Carmustine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Carmustine may decrease the excretion rate of Gadoteridol which could result in a higher serum level. Gallium nitrate The risk or severity of adverse effects can be increased when Carmustine is combined with Gallium nitrate. Ganciclovir Carmustine may decrease the excretion rate of Ganciclovir which could result in a higher serum level. Gatifloxacin The metabolism of Carmustine can be decreased when combined with Gatifloxacin. Gemcitabine The risk or severity of adverse effects can be increased when Carmustine is combined with Gemcitabine. Gemfibrozil The metabolism of Carmustine can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Carmustine can be decreased when combined with Gemifloxacin. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine. Gentamicin Carmustine may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gimeracil Carmustine may decrease the excretion rate of Gimeracil which could result in a higher serum level. Givosiran The serum concentration of Carmustine can be increased when it is combined with Givosiran. Glatiramer The risk or severity of adverse effects can be increased when Carmustine is combined with Glatiramer. Glipizide Carmustine may decrease the excretion rate of Glipizide which could result in a higher serum level. Glycerol phenylbutyrate Carmustine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Golimumab The metabolism of Carmustine can be increased when combined with Golimumab. Golodirsen Carmustine may decrease the excretion rate of Golodirsen which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level. Grepafloxacin The metabolism of Carmustine can be decreased when combined with Grepafloxacin. Guanabenz The metabolism of Guanabenz can be decreased when combined with Carmustine. Guanethidine Carmustine may decrease the excretion rate of Guanethidine which could result in a higher serum level. Guanfacine Carmustine may decrease the excretion rate of Guanfacine which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Carmustine is combined with Guselkumab. Lumiracoxib Lumiracoxib may decrease the excretion rate of Carmustine which could result in a higher serum level. Macitentan Carmustine may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Carmustine. Magnesium carbonate Carmustine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chloride Carmustine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium hydroxide Carmustine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium trisilicate Carmustine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Carmustine may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Mannitol Mannitol may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline The metabolism of Maprotiline can be decreased when combined with Carmustine. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Carmustine. Mecamylamine Carmustine may decrease the excretion rate of Mecamylamine which could result in a higher serum level. Mechlorethamine The risk or severity of adverse effects can be increased when Carmustine is combined with Mechlorethamine. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Carmustine which could result in a higher serum level. Medroxyprogesterone Carmustine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Carmustine. Megestrol acetate Carmustine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. Melatonin The metabolism of Melatonin can be decreased when combined with Carmustine. Meloxicam The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Meloxicam. Melphalan The risk or severity of pulmonary toxicity can be increased when Melphalan is combined with Carmustine. Memantine Carmustine may decrease the excretion rate of Memantine which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Carmustine. Meperidine Carmustine may decrease the excretion rate of Meperidine which could result in a higher serum level. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Carmustine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Carmustine is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Carmustine is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Carmustine is combined with Mercaptopurine. Meropenem Carmustine may decrease the excretion rate of Meropenem which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Carmustine which could result in a higher serum level. Metamfetamine Carmustine may decrease the excretion rate of Metamfetamine which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Carmustine which could result in a higher serum level. Metaxalone Carmustine may decrease the excretion rate of Metaxalone which could result in a higher serum level. Metformin Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level. Methadone Carmustine may decrease the excretion rate of Methadone which could result in a higher serum level. Methazolamide Methazolamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Methimazole The risk or severity of adverse effects can be increased when Carmustine is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Carmustine is combined with Methotrexate. Methoxsalen The metabolism of Carmustine can be decreased when combined with Methoxsalen. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmustine. Methyldopa Carmustine may decrease the excretion rate of Methyldopa which could result in a higher serum level. Methylene blue The metabolism of Carmustine can be increased when combined with Methylene blue. Methylnaltrexone Carmustine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. Methylprednisolone The risk or severity of adverse effects can be increased when Carmustine is combined with Methylprednisolone. Methyltestosterone Carmustine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Carmustine. Metolazone Metolazone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Carmustine may decrease the excretion rate of Metoprolol which could result in a higher serum level. Metyrapone Carmustine may decrease the excretion rate of Metyrapone which could result in a higher serum level. Mexiletine The metabolism of Carmustine can be decreased when combined with Mexiletine. Mianserin The metabolism of Mianserin can be decreased when combined with Carmustine. Midazolam Carmustine may decrease the excretion rate of Midazolam which could result in a higher serum level. Migalastat Carmustine may decrease the excretion rate of Migalastat which could result in a higher serum level. Milnacipran Carmustine may decrease the excretion rate of Milnacipran which could result in a higher serum level. Milrinone Milrinone may decrease the excretion rate of Carmustine which could result in a higher serum level. Mirabegron Carmustine may decrease the excretion rate of Mirabegron which could result in a higher serum level. Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Carmustine. Mitomycin The risk or severity of adverse effects can be increased when Carmustine is combined with Mitomycin. Mitoxantrone The risk or severity of adverse effects can be increased when Carmustine is combined with Mitoxantrone. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Carmustine. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Carmustine. Mometasone furoate The risk or severity of adverse effects can be increased when Carmustine is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Carmustine is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Carmustine is combined with Mosunetuzumab. Moxifloxacin The metabolism of Carmustine can be decreased when combined with Moxifloxacin. Moxisylyte Carmustine may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Norfloxacin The metabolism of Carmustine can be decreased when combined with Norfloxacin. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Carmustine. Obeticholic acid The metabolism of Carmustine can be decreased when combined with Obeticholic acid. Obinutuzumab The risk or severity of adverse effects can be increased when Carmustine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Carmustine. Octinoxate Carmustine may decrease the excretion rate of Octinoxate which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Carmustine is combined with Ofatumumab. Olanzapine The metabolism of Olanzapine can be decreased when combined with Carmustine. Olaparib The risk or severity of adverse effects can be increased when Carmustine is combined with Olaparib. Olsalazine Olsalazine may decrease the excretion rate of Carmustine which could result in a higher serum level. Omeprazole The metabolism of Carmustine can be increased when combined with Omeprazole. Ondansetron The metabolism of Ondansetron can be decreased when combined with Carmustine. Opium Carmustine may decrease the excretion rate of Opium which could result in a higher serum level. Orphenadrine The metabolism of Carmustine can be decreased when combined with Orphenadrine. Oseltamivir Oseltamivir may decrease the excretion rate of Carmustine which could result in a higher serum level. Osilodrostat The metabolism of Carmustine can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Carmustine can be decreased when it is combined with Osimertinib. Ouabain Ouabain may decrease the cardiotoxic activities of Carmustine. Oxacillin Carmustine may decrease the excretion rate of Oxacillin which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Carmustine is combined with Oxaliplatin. Oxaprozin Oxaprozin may decrease the excretion rate of Carmustine which could result in a higher serum level. Oxazepam Carmustine may decrease the excretion rate of Oxazepam which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Oxetacaine. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Carmustine. Oxybenzone Carmustine may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Oxybuprocaine. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Carmustine which could result in a higher serum level. Oxyquinoline Carmustine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Ozanimod The risk or severity of adverse effects can be increased when Carmustine is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Carmustine is combined with Paclitaxel. Pacritinib The metabolism of Carmustine can be decreased when combined with Pacritinib. Palbociclib The risk or severity of adverse effects can be increased when Carmustine is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Carmustine. Paliperidone Carmustine may decrease the excretion rate of Paliperidone which could result in a higher serum level. Palonosetron Carmustine may decrease the excretion rate of Palonosetron which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Carmustine which could result in a higher serum level. Panobinostat The risk or severity of adverse effects can be increased when Carmustine is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Carmustine which could result in a higher serum level. Parecoxib Parecoxib may decrease the excretion rate of Carmustine which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Carmustine. Paromomycin Paromomycin may decrease the excretion rate of Carmustine which could result in a higher serum level. Paroxetine The metabolism of Paroxetine can be decreased when combined with Carmustine. Patent Blue Carmustine may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of adverse effects can be increased when Carmustine is combined with Pazopanib. Pefloxacin The metabolism of Carmustine can be decreased when combined with Pefloxacin. Pegaptanib Carmustine may decrease the excretion rate of Pegaptanib which could result in a higher serum level. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine. Pegcetacoplan The risk or severity of adverse effects can be increased when Carmustine is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Carmustine. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine. Peginterferon alfa-2b The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Carmustine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Carmustine is combined with Pemetrexed. Penbutolol Carmustine may decrease the excretion rate of Penbutolol which could result in a higher serum level. Penciclovir The metabolism of Penciclovir can be decreased when combined with Carmustine. Penicillamine The risk or severity of adverse effects can be increased when Carmustine is combined with Penicillamine. Pentaerythritol tetranitrate Carmustine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. Pentamidine Pentamidine may decrease the excretion rate of Carmustine which could result in a higher serum level. Pentastarch Carmustine may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Carmustine may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Carmustine may decrease the excretion rate of Pentobarbital which could result in a higher serum level. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Carmustine. Pentostatin The risk or severity of adverse effects can be increased when Carmustine is combined with Pentostatin. Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Carmustine. Perampanel The metabolism of Perampanel can be decreased when combined with Carmustine. Perindopril Carmustine may decrease the excretion rate of Perindopril which could result in a higher serum level. Permethrin Carmustine may decrease the excretion rate of Permethrin which could result in a higher serum level. Perphenazine The metabolism of Perphenazine can be decreased when combined with Carmustine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Carmustine. Pertuzumab The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Pertuzumab. Phenazopyridine Phenazopyridine may decrease the excretion rate of Carmustine which could result in a higher serum level. Phenelzine Carmustine may decrease the excretion rate of Phenelzine which could result in a higher serum level. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Carmustine. Phenol The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Carmustine. Phentolamine Carmustine may decrease the excretion rate of Phentolamine which could result in a higher serum level. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine. Phenylbutazone Phenylbutazone may decrease the excretion rate of Carmustine which could result in a higher serum level. Phenylephrine The metabolism of Carmustine can be increased when combined with Phenylephrine. Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Carmustine. Pholcodine Carmustine may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Carmustine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Carmustine may decrease the excretion rate of Phylloquinone which could result in a higher serum level. Picosulfuric acid Carmustine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine. Pimozide The metabolism of Pimozide can be decreased when combined with Carmustine. Pindolol Carmustine may decrease the excretion rate of Pindolol which could result in a higher serum level. Piperacillin Carmustine may decrease the excretion rate of Piperacillin which could result in a higher serum level. Piracetam Carmustine may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Pirfenidone The risk or severity of adverse effects can be increased when Carmustine is combined with Pirfenidone. Piroxicam Piroxicam may decrease the excretion rate of Carmustine which could result in a higher serum level. Pitolisant The metabolism of Carmustine can be increased when combined with Pitolisant. Plazomicin Carmustine may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Carmustine may decrease the excretion rate of Plerixafor which could result in a higher serum level. Polythiazide Polythiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide The risk or severity of adverse effects can be increased when Carmustine is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Carmustine is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Carmustine is combined with Ponesimod. Pramocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Carmustine. Praziquantel The metabolism of Praziquantel can be decreased when combined with Carmustine. Prednisolone The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisone. Pregabalin Pregabalin may decrease the excretion rate of Carmustine which could result in a higher serum level. Prilocaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Prilocaine. Primaquine The metabolism of Carmustine can be increased when combined with Primaquine. Primidone The metabolism of Carmustine can be increased when combined with Primidone. Probenecid Carmustine may decrease the excretion rate of Probenecid which could result in a higher serum level. Procainamide Carmustine may decrease the excretion rate of Procainamide which could result in a higher serum level. Procaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Procaine. Procaine Carmustine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Procarbazine The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine. Promazine The metabolism of Carmustine can be decreased when combined with Promazine. Promethazine Carmustine may decrease the excretion rate of Promethazine which could result in a higher serum level. Propafenone The metabolism of Carmustine can be decreased when combined with Propafenone. Propantheline Carmustine may decrease the excretion rate of Propantheline which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Proparacaine. Propiverine Carmustine may decrease the excretion rate of Propiverine which could result in a higher serum level. Propoxycaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be decreased when combined with Carmustine. Propylthiouracil The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Carmustine. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Carmustine. Prucalopride Carmustine may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Carmustine may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Carmustine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. Pyridoxine Pyridoxine may decrease the excretion rate of Carmustine which could result in a higher serum level. Pyrithione Carmustine may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine Carmustine may decrease the excretion rate of Quetiapine which could result in a higher serum level. Quinethazone Quinethazone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. Quinidine The metabolism of Carmustine can be decreased when combined with Quinidine. Quinine The metabolism of Quinine can be decreased when combined with Carmustine. Rabeprazole Carmustine may decrease the excretion rate of Rabeprazole which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Carmustine. Rabies virus A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carmustine. Rabies virus B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Carmustine. Raltitrexed The risk or severity of adverse effects can be increased when Carmustine is combined with Raltitrexed. Ramelteon The metabolism of Ramelteon can be decreased when combined with Carmustine. Ranitidine The metabolism of Ranitidine can be decreased when combined with Carmustine. Ranolazine Ranolazine may decrease the excretion rate of Carmustine which could result in a higher serum level. Rasagiline The metabolism of Rasagiline can be decreased when combined with Carmustine. Ravulizumab The risk or severity of adverse effects can be increased when Carmustine is combined with Ravulizumab. Reserpine Reserpine may decrease the excretion rate of Carmustine which could result in a higher serum level. Resorcinol Carmustine may decrease the excretion rate of Resorcinol which could result in a higher serum level. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Carmustine. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Carmustine. Ribavirin Carmustine may decrease the excretion rate of Ribavirin which could result in a higher serum level. Ribostamycin Carmustine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rifampicin The metabolism of Carmustine can be increased when combined with Rifampicin. Rifamycin The metabolism of Carmustine can be decreased when combined with Rifamycin. Rilonacept The metabolism of Carmustine can be increased when combined with Rilonacept. Riluzole The metabolism of Riluzole can be decreased when combined with Carmustine. Risankizumab The risk or severity of adverse effects can be increased when Carmustine is combined with Risankizumab. Ritonavir The metabolism of Carmustine can be increased when combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine. Rivaroxaban Carmustine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Carmustine may decrease the excretion rate of Rizatriptan which could result in a higher serum level. Rofecoxib The metabolism of Carmustine can be decreased when combined with Rofecoxib. Roflumilast Roflumilast may increase the immunosuppressive activities of Carmustine. Ropeginterferon The risk or severity of adverse effects can be increased when Carmustine is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Ropivacaine. Rosiglitazone Carmustine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. Rosoxacin The metabolism of Carmustine can be decreased when combined with Rosoxacin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Carmustine. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Carmustine. Rucaparib The metabolism of Carmustine can be increased when combined with Rucaparib. Ruxolitinib The risk or severity of adverse effects can be increased when Carmustine is combined with Ruxolitinib. Sacubitril Carmustine may decrease the excretion rate of Sacubitril which could result in a higher serum level. Salbutamol Carmustine may decrease the excretion rate of Salbutamol which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Carmustine which could result in a higher serum level. Salicylic acid Salicylic acid may decrease the excretion rate of Carmustine which could result in a higher serum level. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Carmustine which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Carmustine which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Carmustine is combined with Sarilumab. Satralizumab The serum concentration of Carmustine can be decreased when it is combined with Satralizumab. Saxagliptin Carmustine may decrease the excretion rate of Saxagliptin which could result in a higher serum level. Secobarbital Carmustine may decrease the excretion rate of Secobarbital which could result in a higher serum level. Secukinumab The metabolism of Carmustine can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Carmustine. Selenious acid Carmustine may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Carmustine may decrease the excretion rate of Selenium which could result in a higher serum level. Selumetinib The metabolism of Selumetinib can be decreased when combined with Carmustine. Sibutramine Carmustine may decrease the excretion rate of Sibutramine which could result in a higher serum level. Siltuximab The metabolism of Carmustine can be increased when combined with Siltuximab. Simeprevir The metabolism of Carmustine can be decreased when combined with Simeprevir. Siponimod The risk or severity of adverse effects can be increased when Carmustine is combined with Siponimod. Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Pregnancy Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. Lactation No information is available on the use of carmustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carmustine.[1] The manufacturer recommends that breastfeeding be discontinued during carmustine therapy and for 1 month after the last dose. How should this medicine be used? Carmustine injection comes as a powder to be added to fluid and injected over at least 2 hours intravenously (into a vein) by a doctor or nurse in a medical office or hospital outpatient clinic. It is usually injected once every 6 weeks. It may also be injected in smaller doses once a day for 2 days in a row every 6 weeks. Your doctor may need to delay your treatment or adjust your dose if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with carmustine. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before receiving a carmustine injection, tell your doctor and pharmacist if you are allergic to carmustine or any of the ingredients in the carmustine injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements, you are taking or plan to take. Be sure to mention any of the following: cimetidine (Tagamet) and phenytoin (Dilantin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Other medications may also interact with carmustine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had kidney or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant while you are receiving carmustine injections. If you become pregnant while receiving carmustine, call your doctor. Carmustine may harm the fetus. References https://pubchem.ncbi.nlm.nih.gov/compound/Carmustine https://go.drugbank.com/drugs/DB00262 https://medlineplus.gov/druginfo/meds/a682060.html https://www.drugs.com/pregnancy/carmustine.html https://www.webmd.com/drugs/2/drug-19920/carmustine-intravenous/details/list-contraindications ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Carmustine [USAN:USP:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0000154938 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Carmustine https://www.drugbank.ca/drugs/DB00262 DTP/NCI https://www.cancer.gov/policies/copyright-reuse carmustine https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=758392 carmustine https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=409962 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources N,N’-Bis(2-chloroethyl)-N-nitrosourea https://comptox.epa.gov/dashboard/DTXSID8022743 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Carmustine https://echa.europa.eu/substance-information/-/substanceinfo/100.005.309 Carmustine https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/21558 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking CARMUSTINE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/U68WG3173Y Hazardous Substances Data Bank (HSDB) Carmustine https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7761 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Carmustine http://www.hmdb.ca/metabolites/HMDB0014407 ChEBI Carmustine http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3423 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking CARMUSTINE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Carmustine https://www.ncbi.nlm.nih.gov/books/n/livertox/Carmustine/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C349 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL513/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D002330 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/CARMUSTINE Therapeutic Target Database (TTD) DTI-015 http://idrblab.net/ttd/data/drug/details/D01OXI ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html CARMUSTINE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CARMUSTINE European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Carmustine Obvius (EMEA/H/C/004326) https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-obvius Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Carmustine https://www.ncbi.nlm.nih.gov/books/NBK500930/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ NITE-CMC 1,3-Bis(2-chloroethyl)-1-nitrosourea, (alias Carmustine) – FY2009 https://www.nite.go.jp/chem/english/ghs/09-mhlw-0228e.html FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking CARMUSTINE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Bischloroethyl nitrosourea (BCNU) https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse BiCNU (Carmustine) https://www.cancer.gov/about-cancer/treatment/drugs/carmustine NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NIST Mass Spectrometry Data Center LICENSE https://www.nist.gov/srd/public-law Carmustine http://www.nist.gov/srd/nist1a.cfm SpectraBase 1-(2-Chloroethyl)-1-([(2-chloroethyl)amino]carbonyl)-2-oxohydrazine https://spectrabase.com/spectrum/73fQc6DWEGO 1,3-BIS-(2-CHLOROETHYL)-1-NITROSOUREA https://spectrabase.com/spectrum/JouNlDITbxU 1,3-BIS-(2-CHLOROETHYL)-1-NITROSOUREA https://spectrabase.com/spectrum/FUCaY5zpoyP 1,3-Bis-(2-chloroethyl)-1-nitrosourea https://spectrabase.com/spectrum/8TQ7XYPzHNm 1,3-Bis-(2-chloroethyl)-1-nitrosourea https://spectrabase.com/spectrum/3kMiqrOt1H1 NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/2105 Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=12051101-340277020 SpringerMaterials Urea, N,N’-bis(2-chloroethyl)-N-nitroso- https://materials.springer.com/substanceprofile/docs/smsid_aiybodkazgirkrhd Thieme Chemistry LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=12051101-340277411 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Carmustine https://www.wikidata.org/wiki/Q415869 Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=141573 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Carmustine https://www.ncbi.nlm.nih.gov/mesh/68002330 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents, Alkylating https://www.ncbi.nlm.nih.gov/mesh/68018906 PubChem https://pubchem.ncbi.nlm.nih.gov KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 403417922 https://pubchem.ncbi.nlm.nih.gov/substance/403417922 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More